Albert Bourla - 15 Dec 2022 Form 4 Insider Report for PFIZER INC (PFE)

Reporting relationship: Chairman & CEO, Director
Issuer ticker: PFE
Reported as of: 15 Dec 2022
Net transaction value: +$6,059,116
SEC form: 4
Accepted by SEC: 16 Dec 2022, 17:14:34 UTC
Prior SEC filing: 01 Dec 2022
Next SEC filing: 03 Jan 2023
Source filing: View source filing
Reporting owner signature: Susan E. Grant, by power of atty., for Albert Bourla

Key filing fact

Albert Bourla filed Form 4 for PFIZER INC (PFE) on 16 Dec 2022.

Key facts

This page summarizes Albert Bourla's Form 4 filing for PFIZER INC (PFE).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 16 Dec 2022, 17:14.

Change

Previous filing in this sequence was filed on 01 Dec 2022.
Current net transaction value: +$6,059,116.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PFE transaction

Common Stock

Options Exercise

Transaction value: $4,017,799
Shares: +133,172
Change %: +70%
Price: $30.17
Shares after: 322,734
Date: 16 Dec 2022
Ownership: Direct
Footnotes: F1

PFE transaction

Common Stock

Options Exercise

Transaction value: $2,040,781
Shares: +89,156
Change %: +28%
Price: $22.89
Shares after: 411,890
Date: 16 Dec 2022
Ownership: Direct
Footnotes: F2

PFE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,146
Date: 15 Dec 2022
Ownership: By Rule 16b-3 Plan

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PFE transaction Derivative

Phantom Stock Units SSP

Award

Transaction value: $536
Shares: +10
Change %: +0.01%
Price: $53.61
Shares after: 96,391
Date: 15 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10
Exercise price
Footnotes: F3, F4

PFE transaction Derivative

Stock Appreciation Rights

Options Exercise

Transaction value: $0
Shares: -285,161
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 285,161
Exercise price: $30.17

PFE transaction Derivative

Stock Appreciation Rights

Options Exercise

Transaction value: $0
Shares: -145,970
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 145,970
Exercise price: $22.89

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.

Footnote F2

Footnote F3

Each unit represents one phantom share of common stock.

Footnote F4

These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.